Medicus Pharma Ltd. Announces First Patient Randomized in Phase 2 Trial of SKNJCT-003 for the Treatment of Nodular Basal Cell Carcinoma in Adults© Invezz Corporate Logo© Invezz ...

On August 27, 2024, Medicus Pharma (TSXV:MDCX) announced that the first patient (of up to 60 subjects) has been randomized in the Phase 2 clinical trial (SKNJCT-003) for the treatment of nodular ...

A randomized, double blind, placebo-controlled, multicenter study, SKNJCT-003 will enroll up to 60 patients with nodular basal cell carcinoma (BCC) in the U.S. Patients will be randomly assigned ...

Superficial curettage plus imiquimod cream 5% in the treatment of nodular basal cell carcinoma showed more treatment failure at 5 years vs. surgical excision, according to a study.“Surgical ...

TOPLINE: In a randomized trial, recurrence was higher after superficial curettage (SC) plus imiquimod cream than surgical excision (SE) in patients with nodular basal cell carcinoma (nBCC ...

Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC) Provided by GlobeNewswire Feb 14, 2025 12:30pm ...

Champion discussed treatment he sought for an unusual mark on his face, which turned out to be nodular basal cell carcinoma, on “Good Morning America” Friday.

Champion discussed treatment he sought for an unusual mark on his face, which turned out to be nodular basal cell carcinoma, on “Good Morning America” Friday. “We started talking about it ...

Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC) Published Feb 14, 2025 7:30am EST ...